These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 11922941)

  • 1. Antibody-mediated neutralization of cytomegalovirus: modulation of efficacy induced through the IgG constant region.
    Furebring C; Speckner A; Mach M; Sandlie I; Norderhaug L; Borrebaeck CA; Turesson H; Ohlin M
    Mol Immunol; 2002 Mar; 38(11):833-40. PubMed ID: 11922941
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Properties of IgG subclasses to human cytomegalovirus.
    Gilljam G; Wahren B
    J Virol Methods; 1989 Aug; 25(2):139-51. PubMed ID: 2550502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neutralization and sensitization of cytomegalovirus by IgG antibody, anti-IgG antibody, and complement.
    Rundell BB; Betts RF
    J Med Virol; 1982; 10(2):109-18. PubMed ID: 6292359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibodies specific for the antigenic domain 1 of glycoprotein B (gpUL55) of human cytomegalovirus bind to different substructures.
    Schoppel K; Hassfurther E; Britt W; Ohlin M; Borrebaeck CA; Mach M
    Virology; 1996 Feb; 216(1):133-45. PubMed ID: 8614980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Binding characteristics determine the neutralizing potential of antibody fragments specific for antigenic domain 2 on glycoprotein B of human cytomegalovirus.
    Lantto J; Fletcher JM; Ohlin M
    Virology; 2003 Jan; 305(1):201-9. PubMed ID: 12504553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential effects of glycoprotein B epitope-specific antibodies on human cytomegalovirus-induced cell-cell fusion.
    Gicklhorn D; Eickmann M; Meyer G; Ohlin M; Radsak K
    J Gen Virol; 2003 Jul; 84(Pt 7):1859-1862. PubMed ID: 12810880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A divalent antibody format is required for neutralization of human cytomegalovirus via antigenic domain 2 on glycoprotein B.
    Lantto J; Fletcher JM; Ohlin M
    J Gen Virol; 2002 Aug; 83(Pt 8):2001-2005. PubMed ID: 12124464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IgG subclass antibodies to human cytomegalovirus (CMV) in normal human plasma samples and immune globulins and their neutralizing activities.
    Gupta CK; Leszczynski J; Gupta RK; Siber GR
    Biologicals; 1996 Jun; 24(2):117-24. PubMed ID: 8889058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibodies to recombinant-derived glycoprotein B after natural human cytomegalovirus infection correlate with neutralizing activity.
    Marshall GS; Rabalais GP; Stout GG; Waldeyer SL
    J Infect Dis; 1992 Feb; 165(2):381-4. PubMed ID: 1309850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A dimerized single-chain variable fragment system for the assessment of neutralizing activity of phage display-selected antibody fragments specific for cytomegalovirus.
    Carlsson F; Trilling M; Perez F; Ohlin M
    J Immunol Methods; 2012 Feb; 376(1-2):69-78. PubMed ID: 22154743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of the presence of cytomegalovirus-neutralizing antibody by a plaque-reduction assay.
    Lewis RB; Matzke DS; Albrecht TB; Pollard RB
    Rev Infect Dis; 1986; 8 Suppl 4():S434-8. PubMed ID: 3018894
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibodies to the major linear neutralizing domains of cytomegalovirus glycoprotein B among natural seropositives and CMV subunit vaccine recipients.
    Marshall GS; Li M; Stout GG; Louthan MV; Duliège AM; Burke RL; Hunt LA
    Viral Immunol; 2000; 13(3):329-41. PubMed ID: 11016597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunoglobulin G3 from polyclonal human immunodeficiency virus (HIV) immune globulin is more potent than other subclasses in neutralizing HIV type 1.
    Scharf O; Golding H; King LR; Eller N; Frazier D; Golding B; Scott DE
    J Virol; 2001 Jul; 75(14):6558-65. PubMed ID: 11413323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subclass-specific antibody responses to human cytomegalovirus in lung transplant recipients and their association with constant heavy immunoglobulin G chain polymorphism and virus replication.
    Simon B; Weseslindtner L; Görzer I; Pollak K; Jaksch P; Klepetko W; Puchhammer-Stöckl E
    J Heart Lung Transplant; 2016 Mar; 35(3):370-377. PubMed ID: 26657280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new look at a poorly immunogenic neutralization epitope on cytomegalovirus glycoprotein B. Is there cause for antigen redesign?
    Ohlin M
    Mol Immunol; 2014 Aug; 60(2):95-102. PubMed ID: 24802891
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of immunoglobulin G preparations for anti-cytomegalovirus antibodies with reference to neutralizing antibody in the presence of complement.
    Eizuru Y; Ueno I; Minamishima Y
    J Clin Microbiol; 1988 Sep; 26(9):1881-3. PubMed ID: 2846652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression and functional activity of isotype and subclass switched human monoclonal antibody reactive with the base of the V3 loop of HIV-1 gp120.
    Liu F; Bergami PL; Duval M; Kuhrt D; Posner M; Cavacini L
    AIDS Res Hum Retroviruses; 2003 Jul; 19(7):597-607. PubMed ID: 12908937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional differences between antiviral activities of sulfonated and intact intravenous immunoglobulin preparations toward varicella-zoster virus and cytomegalovirus.
    Yajima M; Shiraki A; Daikoku T; Oyama Y; Yoshida Y; Shiraki K
    J Infect Chemother; 2015 Jun; 21(6):427-33. PubMed ID: 25824903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and characterization of a novel fusion protein composed of a human IgG1 heavy chain constant region and a single-chain fragment variable antibody against Venezuelan equine encephalitis virus.
    Hu WG; Alvi AZ; Chau D; Coles JE; Fulton RE; Suresh MR; Nagata LP
    J Biochem; 2003 Jan; 133(1):59-66. PubMed ID: 12761199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant modified vaccinia virus Ankara expressing a soluble form of glycoprotein B causes durable immunity and neutralizing antibodies against multiple strains of human cytomegalovirus.
    Wang Z; La Rosa C; Maas R; Ly H; Brewer J; Mekhoubad S; Daftarian P; Longmate J; Britt WJ; Diamond DJ
    J Virol; 2004 Apr; 78(8):3965-76. PubMed ID: 15047812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.